Jiaxi Shen

Jiaxi Shen

Auto-generated profile, based on publicly available information

Jiaxi Shen

Sun Yat-sen University Cancer Center 1 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer Guangzhou, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2026 in Cancer Research
Verified
Journal Article
Closed access
YZYuheng Zhao
Yuheng Zhao
COChunxian Ou
Chunxian Ou
HHHuimin Huang
Huimin Huang
YWYujue Wang
Yujue Wang
JSJiaxi Shen
Jiaxi Shen
YLYingqin Li
Yingqin Li
Metabolic reprogramming under therapeutic stress may represent a targetable vulnerability for cancer treatment. Elucidation of the metabolic alterations linked to chemotherapy in nasopharyngeal carcinoma (NPC) could uncover potential therapeutic strategies. Using proteomics and transcriptomic profiles, we identified wild-type (WT) isocitrate dehydrogenase 1 (IDH1) as a crucial metabolic enzyme upregulated in gemcitabine plus cisplatin (GP) chemotherapy–resistant NPC. IDH1 reprogrammed nucleotide metabolism in response to chemotherapy, linking DNA damage repair (DDR) to ferroptosis resistance via dihydroorotate dehydrogenase (DHODH), thereby contributing to chemoresistance in NPC. Mechanistically, α-ketoglutarate (αKG), a metabolite of IDH1, enhanced chromatin accessibility to promote DHODH transcription via αKG-dependent dioxygenase AlkB homolog 5 (ALKBH5)–recruited heterogeneous nuclear ribonucleoprotein C (HNRNPC). The DHODH inhibitor BAY2402234 markedly sensitized NPC cells to chemotherapy. Clinically, a prognostic model based on DDR and ferroptosis signatures effectively predicted disease relapse risk following chemotherapy in NPC. This study links DDR to ferroptosis defense via the IDH1/αKG/ALKBH5/DHODH axis, suggesting DHODH inhibition as a promising therapeutic strategy to overcome chemoresistance in tumors harboring WT IDH1. Significance: DHODH-mediated nucleotide metabolic reprogramming represents a targetable vulnerability to counteract chemoresistance in nasopharyngeal carcinoma with wild-type IDH1 overexpression.

17 June 2026
Verified
Other
Open access
YZYuheng Zhao
Yuheng Zhao
COChunxian Ou
Chunxian Ou
HHHuimin Huang
Huimin Huang
YWYujue Wang
Yujue Wang
JSJiaxi Shen
Jiaxi Shen
YLYingqin Li
Yingqin Li
Supplementary Figure S9. DHODH inhibition enhances GP-induced ferroptosis and antitumor efficacy with systemic safety maintained in NPC cells and xenograft models.

17 June 2026
Verified
Other
Open access
YZYuheng Zhao
Yuheng Zhao
COChunxian Ou
Chunxian Ou
HHHuimin Huang
Huimin Huang
YWYujue Wang
Yujue Wang
JSJiaxi Shen
Jiaxi Shen
YLYingqin Li
Yingqin Li
Supplementary Figure S5. IDH1-mediated αKG regulates DHODH expression through ALKBH5.

17 June 2026
Verified
Other
Open access
YZYuheng Zhao
Yuheng Zhao
COChunxian Ou
Chunxian Ou
HHHuimin Huang
Huimin Huang
YWYujue Wang
Yujue Wang
JSJiaxi Shen
Jiaxi Shen
YLYingqin Li
Yingqin Li
Table S1-S7 Supplementary Table S1. Primers and RNA sequences used in this study. Supplementary Table S2. Gene sets used for generating the DDRFP classifier. Supplementary Table S3. Differentially expressed proteins identified by proteomics. Supplementary Table S4. Bulk RNA-seq analysis of core nucleotide metabolic enzyme genes in CTRL and IDH1-KO HK-1 cells. Supplementary Table S5. Pearson correlation analysis between IDH1 and α-KG dependent demethylases. Supplementary Table S6. Anti-ALKBH5 IP-specific proteins identified via mass spectrometry. Supplementary Table S7. Clinical characteristics of patients in the training and validation cohorts, stratified by the ssGSEA classifier.

17 June 2026
Verified
Other
Open access
YZYuheng Zhao
Yuheng Zhao
COChunxian Ou
Chunxian Ou
HHHuimin Huang
Huimin Huang
YWYujue Wang
Yujue Wang
JSJiaxi Shen
Jiaxi Shen
YLYingqin Li
Yingqin Li
Supplementary Figure S6. IDH1-activated ALKBH5 recruits HNRNPC for chromatin remodeling to enhance DHODH transcription.

17 June 2026
Verified
Other
Open access
YZYuheng Zhao
Yuheng Zhao
COChunxian Ou
Chunxian Ou
HHHuimin Huang
Huimin Huang
YWYujue Wang
Yujue Wang
JSJiaxi Shen
Jiaxi Shen
YLYingqin Li
Yingqin Li
Supplementary Figure S2. IDH1 modulates GP-induced DNA damage in NPC cells.